TrialOncoimmunology2025

XL888 and pembrolizumab modulate the immune landscape of colorectal tumors in a phase Ib/II clinical trial.

Maggie J Phillips et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.